Capmatinib
- Generic Name
- Capmatinib
- Brand Names
- Tabrecta
- Drug Type
- Small Molecule
- Chemical Formula
- C23H17FN6O
- CAS Number
- 1029712-80-8
- Unique Ingredient Identifier
- TY34L4F9OZ
- Background
Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many...
- Indication
用于治疗局部晚期或转移性MET外显子14跳跃（METEX 14）突变的非小细胞肺癌（NSCLC）患者。
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Unresectable, locally advanced Non-Small Cell Lung Carcinoma (NSCLC)
- Associated Therapies
- -
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT04816214
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04741789
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 37
- Registration Number
- NCT04677595
- Locations
- 🇨🇳
Novartis Investigative Site, Tianjin, China
A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04460729
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 22
- Registration Number
- NCT04427072
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 31
- Registration Number
- NCT04323436
- Locations
- 🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
🇺🇸Massachusetts General Hospital Liver and Kidney TX, Boston, Massachusetts, United States
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%
- Conditions
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT04139317
- Locations
- 🇹🇭
Novartis Investigative Site, Bangkok, Thailand
Molecular Profiling of Advanced Soft-tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-12-21
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 603
- Registration Number
- NCT03784014
- Locations
- 🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷IUCT Oncopôle, Toulouse, France
🇫🇷Institut de Cancérologie de Montpellier, Montpellier, France
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
- Conditions
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 64
- Registration Number
- NCT03742349
- Locations
- 🇺🇸
Columbia University Medical Center- New York Presbyterian Columbia, New York, New York, United States
🇪🇸Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
🇺🇸Sarah Cannon Research Institute Sarah Cannon Research, Nashville, Tennessee, United States
Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 27
- Registration Number
- NCT03693339
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.